methane and Bowel Diseases, Inflammatory studies

Methane: The simplest saturated hydrocarbon. It is a colorless, flammable gas, slightly soluble in water. It is one of the chief constituents of natural gas and is formed in the decomposition of organic matter. (Grant & Hackh's Chemical Dictionary, 5th ed)
methane : A one-carbon compound in which the carbon is attached by single bonds to four hydrogen atoms. It is a colourless, odourless, non-toxic but flammable gas (b.p. -161degreeC).

Research Excerpts

Excerpt	Relevance	Reference
"Lactose intolerance is the most prevalent intestinal malabsorption disorder."	8.91	[Lactose intolerance: past and present. Part 1]. ( Buzás, GM, 2015)
"Lactose intolerance is the most prevalent intestinal malabsorption disorder."	4.91	[Lactose intolerance: past and present. Part 1]. ( Buzás, GM, 2015)
"Hydrogen-rich water has a significant protective effect on OGD/R-causing HT22 cell injury, and the mechanism may be related to the inhibition of autophagy."	4.40	Effect of 12-week of aerobic exercise on hormones and lipid profile status in adolescent girls with polycystic ovary syndrome: A study during COVID-19. ( , 2023)
" Since there are two gases (hydrogen and methane) measured on lactulose breath testing, we evaluated whether the different gas patterns on lactulose breath testing coincide with diarrhea and constipation symptoms in IBS and IBD."	3.72	Methane production during lactulose breath test is associated with gastrointestinal disease presentation. ( Chow, EJ; Hasan, A; Kong, Y; Mayer, AG; Park, S; Pimentel, M, 2003)
"Hydrogen sulphide is a by-product of H(2) metabolism by SRB, which are ubiquitous in the colonic mucosa."	2.48	Contributions of the microbial hydrogen economy to colonic homeostasis. ( Benefiel, AC; Carbonero, F; Gaskins, HR, 2012)

Research

Studies (12)

Authors

Clinical Trials (1)

Trial Overview

Trial Outcomes

Change From Baseline in Breath Methane Production Based on a Single-point Breath Methane Test

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (8.33)	29.6817
2010's	8 (66.67)	24.3611
2020's	3 (25.00)	2.80

Authors	Studies
Shen, N	1
Wang, Z	1
Wang, C	1
Zhang, J	1
Liu, C	1
Ding, XW	1
Liu, YX	1
Fang, XC	1
Liu, K	1
Wei, YY	1
Shan, MH	1
Ross, EM	1
Moate, PJ	1
Marett, LC	1
Cocks, BG	1
Hayes, BJ	1
Lee, JM	1
Lee, KM	1
Chung, YY	1
Lee, YW	1
Kim, DB	1
Sung, HJ	1
Chung, WC	1
Paik, CN	1
Buzás, GM	1
Eadala, P	1
Matthews, SB	1
Waud, JP	1
Green, JT	1
Campbell, AK	1
Nakamura, N	1
Lin, HC	1
McSweeney, CS	1
Mackie, RI	1
Gaskins, HR	2
Carbonero, F	1
Benefiel, AC	1
Pimentel, M	1
Mayer, AG	1
Park, S	1
Chow, EJ	1
Hasan, A	1
Kong, Y	1
Yue, NN	1
Xu, HM	1
Xu, J	1
Zhu, MZ	1
Zhang, Y	1
Tian, CM	1
Nie, YQ	1
Yao, J	1
Liang, YJ	1
Li, DF	1
Wang, LS	1
Wang, Q	1
Subramanian, P	1
Schechter, A	1
Teblum, E	1
Yemini, R	1
Nessim, GD	1
Vasilescu, A	1
Li, M	1
Boukherroub, R	1
Szunerits, S	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
Evaluation of the Efficacy and Safety of Single, Daily Oral Doses of SYN-010 Compared to Placebo in Adult Patients With Irritable Bowel Syndrome With Constipation (EASE-DO)[NCT03763175]	Phase 2	59 participants (Actual)	Interventional	2018-12-24	Terminated (stopped due to Interim Futility Analysis)
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Change in exhaled methane level as a potential predictor of constipation improvement will be evaluated by comparing single-point breath tests pre- and post-treatment. (NCT03763175)
Timeframe: After completing course of SYN-010

Change From Baseline in the Weekly Average Number of Completely Spontaneous Bowel Movements (CSBM) Compared to the 12-week Treatment Period

Intervention	particles per million (Mean)
SYN-010 21 mg	-22.623
SYN-010 42 mg	-4.785
Placebo	-10.081

Subjects will record their daily bowel movements throughout the duration of the study. Change in weekly average number of CSBMs will be evaluated by comparing reported values pre- and post-treatment. (NCT03763175)
Timeframe: After completing 12-week course of SYN-010

Mean Change From Baseline in the Area-under-the-curve (AUC) of Breath Methane Production, Based on the 120-minute Lactulose Breath Test.

Intervention	Weekly average CSBMs (Least Squares Mean)
SYN-010 21 mg	1.53
SYN-010 42 mg	0.32
Placebo	0.51

Change in exhaled methane level as a potential predictor of constipation improvement will be evaluated by comparing lactulose breath tests pre- and post-treatment. (NCT03763175)
Timeframe: After completing 12-week course of SYN-010

Proportion of Overall Abdominal Pain Intensity Responders During the 12-week Treatment Period

Intervention	particles per million * min (Mean)
SYN-010 21 mg	-18.678
SYN-010 42 mg	-20.137
Placebo	-39.199

An overall abdominal pain intensity responder is defined as a patient with a weekly abdominal pain intensity response in at least 50% of the weeks of treatment (6 of 12 weeks). A weekly response abdominal pain intensity response is defined as a decrease in the patient's weekly average score for worst abdominal pain in the past 24 hours of at least 30% compared to baseline, with stool frequency unchanged or improved compared with baseline. (NCT03763175)
Timeframe: After completing 12-week course of SYN-010

Proportion of Overall Bloating Responders During the 12-week Treatment Period

Intervention	Participants (Count of Participants)
SYN-010 21 mg	4
SYN-010 42 mg	4
Placebo	7

An overall bloating responder is defined as a patient with a weekly bloating response in at least 50% of the weeks of treatment (6 of 12 weeks). A weekly bloating response is defined as a weekly average bloating score of at least 30% improvement compared to baseline, with stool frequency unchanged or improved compared with baseline. (NCT03763175)
Timeframe: After completing 12-week course of SYN-010

Proportion of Overall Responders During the 12-week Treatment Period

Intervention	Participants (Count of Participants)
SYN-010 21 mg	3
SYN-010 42 mg	3
Placebo	1

An overall 12-week responder is defined as a patient with a weekly response in at least 50% of the weeks of treatment (6 of 12 weeks). A weekly response is defined as a decrease in the patient's weekly average score for worst abdominal pain in the past 24 hours of at least 30% compared to baseline and a stool frequency increase of 1 or more CSBMs per week compared with baseline. (NCT03763175)
Timeframe: After completing 12-week course of SYN-010

Proportion of Overall Stool Frequency Responders During the 12-week Treatment Period

Intervention	Participants (Count of Participants)
SYN-010 21 mg	1
SYN-010 42 mg	2
Placebo	6

An overall stool frequency responder is defined as a patient with a weekly stool frequency response in at least 50% of the weeks of treatment (6 of 12 weeks). A weekly stool frequency response is defined as a stool frequency increase of 1 or more CSBMs per week compared with baseline, with abdominal pain unchanged or improved compared with baseline. (NCT03763175)
Timeframe: After completing 12-week course of SYN-010

Proportion of Patients Using Rescue Medication

Intervention	Participants (Count of Participants)
SYN-010 21 mg	4
SYN-010 42 mg	6
Placebo	9

Subjects will record their use of rescue medication throughout the study period. Proportion of patients using rescue medication after completing the 12-week course of treatment will be compared to those reporting usage at baseline screening period. (NCT03763175)
Timeframe: After completing 12-week course of SYN-010

Proportion of Patients With Adequate Relief

Intervention	Participants (Count of Participants)
SYN-010 21 mg	9
SYN-010 42 mg	11
Placebo	8

Outcome will be assessed by evaluating proportion of patients reporting adequate relief pre- and post-treatment on validated questionnaire. (NCT03763175)
Timeframe: After completing 12-week course of SYN-010

Article	Year
[Lactose intolerance: past and present. Part 1]. Orvosi hetilap, 2015, Sep-20, Volume: 156, Issue:38 Topics: Animals; Biopsy; Breath Tests; Celiac Disease; Europe; Genetic Testing; Global Health; History, 17th	2015
Mechanisms of microbial hydrogen disposal in the human colon and implications for health and disease. Annual review of food science and technology, 2010, Volume: 1 Topics: Acetic Acid; Colon; Colorectal Neoplasms; Humans; Hydrogen; Inflammatory Bowel Diseases; Methane; Me	2010
Contributions of the microbial hydrogen economy to colonic homeostasis. Nature reviews. Gastroenterology & hepatology, 2012, Volume: 9, Issue:9 Topics: Bacteria; Carbon Dioxide; Colon; Colonic Diseases; Colorectal Neoplasms; Homeostasis; Humans; Hydrog	2012
Effect of 12-week of aerobic exercise on hormones and lipid profile status in adolescent girls with polycystic ovary syndrome: A study during COVID-19. Science & sports, 2023, Apr-04 Topics: Actin Cytoskeleton; Actins; Adaptor Proteins, Signal Transducing; Adenocarcinoma; Adenosine Triphosp	2023
Application of Nanoparticles in the Diagnosis of Gastrointestinal Diseases: A Complete Future Perspective. International journal of nanomedicine, 2023, Volume: 18 Topics: Gastrointestinal Diseases; Gastrointestinal Neoplasms; Humans; Inflammatory Bowel Diseases; Nanopart	2023

Article	Year
Methane Alleviates Inflammation and Apoptosis of Dextran Sulfate Sodium-Induced Inflammatory Bowel Diseases by Inhibiting Toll-Like Receptor 4 (TLR4)/Myeloid Differentiation Factor 88 (MyD88)/Nuclear Translocation of Nuclear Factor-κB (NF-κB) and Endoplas Medical science monitor : international medical journal of experimental and clinical research, 2020, Jun-05, Volume: 26 Topics: Animals; Anti-Inflammatory Agents; Apoptosis; Dextran Sulfate; Disease Models, Animal; Endoplasmic R	2020
The relationship between small intestinal bacterial overgrowth and irritable bowel syndrome. European review for medical and pharmacological sciences, 2017, Volume: 21, Issue:22 Topics: Adult; Aged; Breath Tests; Female; Gastrointestinal Agents; Gastrointestinal Transit; Humans; Hydrog	2017
Metagenomic predictions: from microbiome to complex health and environmental phenotypes in humans and cattle. PloS one, 2013, Volume: 8, Issue:9 Topics: Animals; Cattle; Environment; Health; Humans; Inflammatory Bowel Diseases; Metagenomics; Methane; Mi	2013
Clinical significance of the glucose breath test in patients with inflammatory bowel disease. Journal of gastroenterology and hepatology, 2015, Volume: 30, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Biomarkers; Breath Tests; Feces; Female; Glucose; Humans; Hydrogen;	2015
Association of lactose sensitivity with inflammatory bowel disease--demonstrated by analysis of genetic polymorphism, breath gases and symptoms. Alimentary pharmacology & therapeutics, 2011, Volume: 34, Issue:7 Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Breath Tests; Chi-Square Distribution; Female;	2011
Methane production during lactulose breath test is associated with gastrointestinal disease presentation. Digestive diseases and sciences, 2003, Volume: 48, Issue:1 Topics: Breath Tests; Colitis, Ulcerative; Constipation; Crohn Disease; Databases, Factual; Gastrointestinal	2003
Vertically Aligned Nitrogen-Doped Carbon Nanotube Carpet Electrodes: Highly Sensitive Interfaces for the Analysis of Serum from Patients with Inflammatory Bowel Disease. ACS applied materials & interfaces, 2016, Apr-20, Volume: 8, Issue:15 Topics: Electrochemistry; Electrodes; Humans; Inflammatory Bowel Diseases; Muramidase; Nanotubes, Carbon; Ni	2016

methane and Bowel Diseases, Inflammatory